Chief Financial Officer · Cartesian Therapeutics, Inc. (RNAC)

Kevin Tan

FY2021 is the first fiscal year CompBrief holds for Kevin Tan as a named executive officer of Cartesian Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,601,622

Salary $110,385Stock awards $0Bonus $75,000

2nd of 7 named executive officers at Cartesian Therapeutics by FY2021 total.

7 named officers on file for Cartesian Therapeutics, FY2021

Kevin Tan’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • RNAC’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cartesian Therapeutics’s whole pay program stands against its peers

  • Cartesian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RNAC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 3, 2022 (DEF 14A).

Free

Get Kevin Tan’s full pay file as a PDF — free

More than this page: up to 10 years of Kevin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kevin Tan compensation by year

Cartesian Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Cartesian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$110,385
Bonus$75,000
Stock awards$0
Option awards$2,369,619
Non-equity incentive$46,280
Pension and deferred compensation$0
All other$338
Total$2,601,622

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cartesian Therapeutics, Inc. DEF 14A filed May 3, 2022, accession 0001453687-22-000071, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cartesian Therapeutics, Inc. filed document, accession 0001453687-22-000071. Every figure is read from that document and cited to the page and table it appears in. Filed May 3, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option750,000—$4.17

Per the Outstanding Equity Awards at Fiscal Year-End table in Cartesian Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Cartesian Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Carsten BrunnPresident and Chief Executive Officer$3,671,395
Kevin Tan · this pageChief Financial Officer$2,601,622
Peter TraberChief Medical Officer$1,600,685
Takashi KishimotoChief Scientific Officer$1,306,675
Lloyd JohnstonChief Operations Officer$1,304,845
Bradford DahmsChief Financial Officer$868,053
Ann DonohueVP, Finance and Corporate Controller, Principal Financial and Accounting Officer$361,493

The full Cartesian Therapeutics compensation record

free company brief

This page is one person within Cartesian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cartesian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cartesian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kevin Tan's compensation dossier · One-time report. No refunds.